An investigation on behalf of investors, who currently hold shares of Ignyta Inc (NASDAQ:RXDX), was announced concerning whether the takeover of Ignyta Inc by Roche for $27.00 per share is unfair to NASDAQ:RXDX stockholders.

The investigation by a law firm concerns whether certain officers and directors of Ignyta Inc breached their fiduciary duties owed to NASDAQ:RXDX investors in connection with the proposed acquisition.

San Diego, CA based Ignyta, Inc. is a biotechnology company focused on precision medicine in oncology. On December 22, 2017, Roche (SIX: RO, ROG; OTCQX: RHHBY) and Ignyta, Inc. (NASDAQ: RXDX) announced they have entered into a definitive merger agreement for Roche to fully acquire Ignyta at a price of US$ 27.00 per share in an all-cash transaction.

However, given that at least one analyst has set the high target price for NASDAQ:RXDX shares at $31.00 per share, the investigation concerns whether the offer is unfair to NASDAQ:RXDX stockholders. More specifically, the investigation concerns whether the Ignyta Board of Directors undertook an adequate sales process, adequately shopped the company before entering into the transaction, maximized shareholder value by negotiating the best price, and acted in the shareholders' best interests in connection with the proposed sale.